Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Genscript Biotech ( (HK:1548) ) is now available.
Genscript Biotech Corporation has updated the terms of reference for its Nomination Committee, emphasizing the importance of diversity and independent oversight. The committee, which consists of at least three directors with a focus on gender diversity and independent non-executive directors, is tasked with reviewing the board’s structure and skills annually to align with the company’s corporate strategy. This move aims to enhance corporate governance and ensure the board’s composition supports strategic goals, potentially impacting stakeholder confidence positively.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation operates in the biotechnology industry, focusing on providing a range of products and services including gene synthesis, peptide synthesis, protein production, and antibody development. The company is known for its innovative solutions in life sciences research and biopharmaceutical development.
Average Trading Volume: 19,110,643
Technical Sentiment Signal: Sell
Current Market Cap: HK$27.48B
Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.